Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Anti-TNF treatment blocks the induction of T cell-dependent humoral responses.

Salinas GF, De Rycke L, Barendregt B, Paramarta JE, Hreggvidstdottir H, Cantaert T, van der Burg M, Tak PP, Baeten D.

Ann Rheum Dis. 2013 Jun;72(6):1037-43. doi: 10.1136/annrheumdis-2011-201270.

PMID:
22968102
2.

Dual role of anti-TNF therapy: enhancement of TCR-mediated T cell activation in peripheral blood and inhibition of inflammation in target tissues.

Bosè F, Raeli L, Garutti C, Frigerio E, Cozzi A, Crimi M, Caprioli F, Scavelli R, Altomare G, Geginat J, Abrignani S, Reali E.

Clin Immunol. 2011 May;139(2):164-76. doi: 10.1016/j.clim.2011.01.015.

PMID:
21334981
3.

Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor.

Kobie JJ, Zheng B, Bryk P, Barnes M, Ritchlin CT, Tabechian DA, Anandarajah AP, Looney RJ, Thiele RG, Anolik JH, Coca A, Wei C, Rosenberg AF, Feng C, Treanor JJ, Lee FE, Sanz I.

Arthritis Res Ther. 2011;13(6):R209. doi: 10.1186/ar3542.

4.
5.

Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists.

Hamdi H, Mariette X, Godot V, Weldingh K, Hamid AM, Prejean MV, Baron G, Lemann M, Puechal X, Breban M, Berenbaum F, Delchier JC, Flipo RM, Dautzenberg B, Salmon D, Humbert M, Emilie D; RATIO (Recherche sur Anti-TNF et Infections Opportunistes) Study Group..

Arthritis Res Ther. 2006;8(4):R114.

6.

Efficacy in current practice of switching between anti-tumour necrosis factor- α agents in spondyloarthropathies.

Paccou J, Solau-Gervais E, Houvenagel E, Salleron J, Luraschi H, Philippe P, Duquesnoy B, Flipo RM.

Rheumatology (Oxford). 2011 Apr;50(4):714-20. doi: 10.1093/rheumatology/keq377.

7.

B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.

Finckh A, Ciurea A, Brulhart L, Kyburz D, Möller B, Dehler S, Revaz S, Dudler J, Gabay C; Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis..

Arthritis Rheum. 2007 May;56(5):1417-23.

8.

The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.

Elkayam O, Caspi D, Reitblatt T, Charboneau D, Rubins JB.

Semin Arthritis Rheum. 2004 Feb;33(4):283-8.

PMID:
14978666
9.

Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis.

Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L.

Rheumatology (Oxford). 2006 Oct;45(10):1294-7.

10.

Cellular interaction in germinal centers. Roles of CD40 ligand and B7-2 in established germinal centers.

Han S, Hathcock K, Zheng B, Kepler TB, Hodes R, Kelsoe G.

J Immunol. 1995 Jul 15;155(2):556-67.

PMID:
7541819
11.

Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study.

Guignard S, Gossec L, Salliot C, Ruyssen-Witrand A, Luc M, Duclos M, Dougados M.

Ann Rheum Dis. 2006 Dec;65(12):1631-4.

12.
13.

Tumour necrosis factor alpha blockade impairs dendritic cell survival and function in rheumatoid arthritis.

Baldwin HM, Ito-Ihara T, Isaacs JD, Hilkens CM.

Ann Rheum Dis. 2010 Jun;69(6):1200-7. doi: 10.1136/ard.2009.110502.

PMID:
19773288
14.

Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors.

Aeberli D, Seitz M, Jüni P, Villiger PM.

Rheumatology (Oxford). 2005 Feb;44(2):172-5.

15.

Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis.

Kapetanovic MC, Saxne T, Sjöholm A, Truedsson L, Jönsson G, Geborek P.

Rheumatology (Oxford). 2006 Jan;45(1):106-11.

16.

TNF blockade abrogates the induction of T cell-dependent humoral responses in an allotransplantation model.

FrancoSalinas G, Mai HL, Jovanovic V, Moizant F, Vanhove B, Boeffard F, Usal C, Tak PP, Soulillou JP, Baeten D, Brouard S.

J Leukoc Biol. 2011 Aug;90(2):367-75. doi: 10.1189/jlb.0710392.

PMID:
21562051
17.

Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways.

Potter C, Cordell HJ, Barton A, Daly AK, Hyrich KL, Mann DA, Morgan AW, Wilson AG; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS)., Isaacs JD.

Ann Rheum Dis. 2010 Jul;69(7):1315-20. doi: 10.1136/ard.2009.117309.

PMID:
20448286
18.

Treatment of spondyloarthritides with anti-TNFalpha biologic agents.

Braun J.

Reumatismo. 2006 Jan-Mar;58 Spec No.1:71-2. No abstract available.

19.

Assessment of patients with spondyloarthropathies for treatment with tumour necrosis factor alpha blockade.

Paul S, Keat A.

Rheumatology (Oxford). 2005 Jan;44(1):17-23. Review. No abstract available.

20.

Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.

Collamer AN, Battafarano DF.

Semin Arthritis Rheum. 2010 Dec;40(3):233-40. doi: 10.1016/j.semarthrit.2010.04.003. Review.

PMID:
20580412
Items per page

Supplemental Content

Support Center